New anabolic therapies in osteoporosis.
While antiresorptive drugs have been the cornerstone of osteoporosis therapy, anabolic drugs are an important new advance in the treatment of osteoporosis. By directly stimulating bone formation, anabolic agents might have greater potential than the antiresorptives to increase bone mass and to decrease fractures. It is also possible that the combination of an antiresorptive agent with an anabolic agent could be more potent than either agent alone. Potential anabolic therapies for osteoporosis, including fluoride, growth hormone, insulin-like growth factor-I, strontium, and parathyroid hormone, are reviewed here. Of these, parathyroid hormone has clearly emerged as the most promising treatment at this time.
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Mishaela R
MR
Rubin
John P
JP
Bilezikian
D019386:Alendronate / Q000627:therapeutic use; D001862:Bone Resorption / Q000378:metabolism / Q000517:prevention & control; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D004359:Drug Therapy, Combination; D005260:Female; D005459:Fluorides / Q000627:therapeutic use; D019382:Human Growth Hormone / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use; D010012:Osteogenesis / Q000187:drug effects / Q000502:physiology*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control; D010281:Parathyroid Hormone / Q000627:therapeutic use; D013324:Strontium / Q000627:therapeutic use
D010281:Parathyroid Hormone; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; D005459:Fluorides; D019386:Alendronate; D013324:Strontium